EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

The Dickkopf-1 (DKK1) Dichotomy in Oncology: New Insights on Tumor Progression and Immune Regulation

Alessandro Canella iD, Zachary Gentry iD, Casey Cosgrove

International Journal of Molecular Sciences · 2026

DOI: 10.3390/ijms27093780 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, 2026. Verfasst von Alessandro Canella und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, The Ohio State University Comprehensive Cancer Center, James Cancer Hospit…. Hauptthemen laut MEDLINE: Intercellular Signaling Peptides and Proteins, Neoplasms. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 117 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: the Sally and Martin Hughes Family Fund for Endometrial Cancer Research.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Dickkopf-1 (DKK1) is a 266-amino-acid secreted glycoprotein originally identified as a high-affinity antagonist of the canonical Wnt/β-catenin signaling pathway and has emerged as a complex regulator in oncology. While historically considered as a tumor suppressor due to its ability to abrogate Wnt-driven proliferation, recent discoveries highlight a paradoxical pro-oncogenic role across various malignancies. The molecular mechanisms by which DKK1 promotes tumor progression, metastasis, and immune evasion are driven by its interaction with cell-surface receptors, specifically LRP5/6 and CKAP4. The DKK1-CKAP4 axis independently activates PI3K/AKT signaling, facilitating epithelial–mesenchymal transition (EMT), chemoresistance, and the formation of osteolytic bone lesions. Furthermore, DKK1 serves as a critical orchestrator of the tumor microenvironment (TME) by driving comprehensive immune reprogramming. It mediates the recruitment of myeloid-derived suppressor cells (MDSCs) and inactivates cytotoxic CD8+ T cells and natural killer (NK) cells, thereby fostering an immunosuppressive tumor microenvironment and resistance to checkpoint inhibitors. Interestingly, cancer-associated fibroblasts (CAFs) are a primary source of DKK1 in the stroma, where they facilitate immune evasion. Clinically, elevated circulating DKK1 levels correlate with advanced disease stages, increased metastatic potential, and poor overall survival in solid and hematological tumors. When used in combination with established biomarkers, serum DKK1 levels demonstrate significant utility for early detection and therapeutic monitoring. Given its intricate impact on malignancy, DKK1 has become a promising therapeutic target, with ongoing clinical trials investigating neutralizing antibodies such as DKN-01 to disrupt its oncogenic and immunosuppressive signaling. Understanding the context-dependent nature of DKK1 signaling remains essential for refining its application as both a biomarker and a component of emerging precision immunotherapy strategies. By prioritizing the literature from the last decade, this review characterizes DKK1 as a key mediator of tumor progression and immune reprogramming, while assessing its clinical potential as a biomarker and therapeutic target.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Intercellular Signaling Peptides and ProteinsNeoplasmsHumansTumor MicroenvironmentAnimalsDisease ProgressionEpithelial-Mesenchymal Transition

Stichwörter der Autor:innen

CKAP4DKK1Dickkopf-1Wntbiomarkerimmunoregulationimmunosuppressionimmunotherapymetastasisoncogene

Substanzen

Intercellular Signaling Peptides and ProteinsDKK1 protein, human

Autor:innen und Institutionen

  • Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, The Ohio State University Comprehensive Cancer Center, James Cancer Hospital, Columbus, OH 43210, USA.

ORCID-Profile: Alessandro Canella, Zachary Gentry

Förderung

  • the Sally and Martin Hughes Family Fund for Endometrial Cancer Research

Zitieren

APA

Canella, A., Gentry, Z., & Cosgrove, C. (2026). The Dickkopf-1 (DKK1) Dichotomy in Oncology: New Insights on Tumor Progression and Immune Regulation. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms27093780

Vancouver

Canella A, Gentry Z, Cosgrove C. The Dickkopf-1 (DKK1) Dichotomy in Oncology: New Insights on Tumor Progression and Immune Regulation. International Journal of Molecular Sciences. 2026. doi:10.3390/ijms27093780

BibTeX
@article{Canella2026,
  author = {Canella, Alessandro and Gentry, Zachary and Cosgrove, Casey},
  title = {The Dickkopf-1 (DKK1) Dichotomy in Oncology: New Insights on Tumor Progression and Immune Regulation},
  journal = {International Journal of Molecular Sciences},
  year = {2026},
  doi = {10.3390/ijms27093780}
}
Kostenlos starten →